Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Healthcare InvestmentA Truist Securities note points to broad recovery signals across biotech, from IPOs and venture funding to large-cap acquisitions driven by patent cliffs. The firm also said regulatory and policy risks have largely played out, with innovation again driving stock performance.
Daniel ChoSep 4, 2026
Regulatory & PolicyAccording to STAT, Clancy sought help from multiple providers in the four months before killing her three children and attempting to kill herself, but those clinicians did not communicate with one another. The report frames the case as an example of a broader structural problem in privately insured U.S. care.
Daniel ChoSep 4, 2026
Biotech InnovationThe patients did not move directly from xenograft to human transplant, with both returning to dialysis for months after the pig kidneys were removed. Even so, the reported outcome suggests the temporary use of gene-edited pig kidneys may not block a later conventional transplant, which is a meaningful operational signal for the field.
Daniel ChoSep 4, 2026
Biopharmaceutical IndustryMedicus will pay $12 million upfront and another $15 million on Sept. 2, 2027, according to an SEC filing, while Pfizer also contributed $2 million to support the program. The transaction shows how large acquirers can keep economic exposure to discontinued assets without carrying full development costs.
Daniel ChoSep 3, 2026
Biopharmaceutical IndustryGSK has licensed worldwide rights to HMPL-A830 outside mainland China, Hong Kong, Macau and Taiwan, where Hutchmed retains control. Initial development will focus on colorectal, pancreatic and lung cancers, with Hutchmed running Phase 1 before GSK takes over later-stage development and commercialization.
Daniel ChoSep 3, 2026
Biotech InnovationThe setback follows Ultragenyx’s recent approval for Genglycos and arrives just weeks before a PDUFA date for UX111 in Sanfilipo syndrome. The failed study also raises commercial and development questions for apazunersen beyond this single trial.
Daniel ChoSep 3, 2026
Medical TechnologyThe FDA issued an early alert after Medtronic sent customers an August 6 letter about the problem. The event matters commercially because it affects a wireless reflux-monitoring device already tied to a June 2025 recall, even though the company said the underlying cause is different this time.
Daniel ChoSep 2, 2026
Biopharmaceutical IndustrySIM0660 targets CD79a, CD19 and CD3 and is being positioned around B-cell-mediated diseases, including certain lymphomas, with Roche saying the collaboration will focus on malignancies. The deal also adds to a growing pattern of Chinese biotechs using out-licensing to monetize early assets before late-stage development.
Daniel ChoSep 1, 2026
Medical TechnologyThe issue centers on reduced levels of stabilizing agents in catheter tips, which could increase the risk of degradation and detachment. For Boston Scientific, the halt adds a device safety problem to a year already marked by a cyberattack, restructuring and lower top-end guidance.
Daniel ChoSep 1, 2026
Healthcare InvestmentThe company plans to list on the Nasdaq Global Select Market under the symbol ETRA and use proceeds to support its immunology and cancer pipeline. Most of the strategic weight sits on ipsoprubart, a monoclonal antibody already in a global phase 2/3 trial and positioned for a potential biologics license application and commercial readiness work.
Daniel ChoSep 1, 2026
Biopharmaceutical IndustryLilly said it will pay up to $2.875 billion, including an upfront payment and contingent milestones, to buy Merida Biosciences, with closing expected in the fourth quarter pending clearances. The acquisition adds MER511 in Phase 1 for thyroid eye disease and Graves’ disease, MER769 in preclinical development for allergic conditions, and a platform designed to selectively target and destroy disease-causing autoantibodies.
Daniel ChoSep 1, 2026
Biopharmaceutical IndustryAkeso described the Harmoni-GI1 result as clinically meaningful and statistically significant on overall survival, with progression-free survival and objective response rate also met. Strategically, the readout broadens the drug’s tumor-type story at a time when debate over changing progression-free survival magnitudes in lung cancer has sharpened attention on what kind of evidence regulators may ultimately value most.
Daniel ChoAug 27, 2026